Podcasts about hematopoiesis

In today's episode, we'll discuss time-limited triplet therapy in relapsed or refractory CLL. Zanubrutinib, venetoclax and obinutuzumab induced deep remissions, and was well tolerated, even in very high-risk patients, and those with prior exposure to targeted therapies. After that: researchers chronicle the development of a patient-reported outcome measure for sclerosis associated with chronic GVHD—graft-versus-host disease. The new symptom scale—currently undergoing validation studies—may provide valuable information regarding severity, functional impact, and response to therapy. Finally, a study of changes in population dynamic rates that underlie inflammation-associated myeloid bias. The work demonstrates the use of mathematical models to deliver critical biological insights and uncover underlying mechanisms.Featured Articles:MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialDevelopment of the Lee Symptom Scale–Skin Sclerosis for chronic GVHD–associated sclerosisPopulation dynamics modeling reveals that myeloid bias involves both HSC differentiation and progenitor proliferation biases

Dr. Cynthia "Cindy" Dunbar is National Institutes of Health (NIH) Distinguished Investigator and Chief of the Translational Stem Cell Biology Branch at the National Heart, Lung, and Blood Institute of the NIH. She talks about using macaques to study hematopoiesis and aging, and the challenges and considerations for using these models. She also discusses her collaborative study transplanting iPSC-derived cardiomyocytes into rhesus macaques, as well as the NIH's unique research environment and her musical talents outside of the lab.

Dr. Irving Weissman is the Virginia and Daniel Ludwig Professor of Clinical Cancer Research and Professor of Pathology and Developmental Biology at Stanford University. Dr. Weissman was the first scientist to identify and isolate mammalian blood-forming stem cells in mice, and his work has contributed to the understanding of how a single hematopoietic stem cell can give rise to specialized blood cells. He talks about developing new treatments for metastatic breast cancer and severe combined immunodeficiency. He also discusses myeloid bias in aging and strategies for commercializing new therapies.

In this episode of the Epigenetics Podcast, we talked with Ana Cvejic from the Biotech Research & Innovation Centre at the University of Copenhagen about her work on using sc-multiomics to characterise human developmental hematopoiesis. The conversation starts by delving into Ana's research on hematopoiesis, starting with her work on identifying novel genes controlling blood traits in zebrafish models. She explains her transition to single-cell methodologies and the application of single-cell RNA sequencing to study hematopoietic cells in zebrafish, focusing on thrombocyte lineage commitment and gene expression. The discussion progresses to her groundbreaking study on human fetal hematopoiesis, where she combined single-cell RNA-seq with single-cell ATAC-seq to understand chromatin accessibility and gene expression dynamics. Ana then shares insights into the identification of new cell surface markers and the priming of hematopoietic stem cells, particularly in conditions like Down syndrome. Furthermore, she then elaborates on the construction of a phylogenetic tree of blood development using whole-genome sequencing of single-cell-derived hematopoietic colonies from healthy human fetuses. She explains the motivation behind this study, highlighting the insights gained regarding stem cell quantities, developmental timelines, and mutations in blood development. References Bielczyk-Maczyńska, E., Serbanovic-Canic, J., Ferreira, L., Soranzo, N., Stemple, D. L., Ouwehand, W. H., & Cvejic, A. (2014). A loss of function screen of identified genome-wide association study Loci reveals new genes controlling hematopoiesis. PLoS genetics, 10(7), e1004450. https://doi.org/10.1371/journal.pgen.1004450 Athanasiadis, E. I., Botthof, J. G., Andres, H., Ferreira, L., Lio, P., & Cvejic, A. (2017). Single-cell RNA-sequencing uncovers transcriptional states and fate decisions in haematopoiesis. Nature communications, 8(1), 2045. https://doi.org/10.1038/s41467-017-02305-6 Ranzoni, A. M., Tangherloni, A., Berest, I., Riva, S. G., Myers, B., Strzelecka, P. M., Xu, J., Panada, E., Mohorianu, I., Zaugg, J. B., & Cvejic, A. (2021). Integrative Single-Cell RNA-Seq and ATAC-Seq Analysis of Human Developmental Hematopoiesis. Cell stem cell, 28(3), 472–487.e7. https://doi.org/10.1016/j.stem.2020.11.015   Related Episodes Single Cell Epigenomics in Neuronal Development (Tim Petros) ATAC-Seq, scATAC-Seq and Chromatin Dynamics in Single-Cells (Jason Buenrostro) Single-Cell Technologies using Microfluidics (Ben Hindson)   Contact Epigenetics Podcast on X Epigenetics Podcast on Instagram Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Epigenetics Podcast on Threads Active Motif on X Active Motif on LinkedIn Email: podcast@activemotif.com

In this Pride Month-themed episode of Hematopoiesis, Drs. Emily Liang, Ajay Major, Michael Hochman, and Shail Maingi discuss career development, community building, and navigating the workforce for LGBTQ+ trainees in hematology.

In this week's episode we'll discuss the utility of MRD in identifying patients with NPM1 AML who benefit from allogeneic transplant in first remission, learn more about the contribution of circulating hematopoietic stem/progenitor cell subsets to human hematopoietic hemostasis, and discuss the role of Let-7 miRNAs in regulation of BCL11A transcription and hemoglobin switching. Featured Articles:Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionlet-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switching Circulating Hematopoietic Stem/Progenitor Cell subsets contribute to human hematopoietic homeostasis

Hanna Mikkola, M.D., Ph.D., shares her work in hematopoietic stem cells (HSCs) and their complex renewal process. Her research aims to unravel these cells' behavior in mice and humans, offering potential insights for future medical advancements. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39258]

Hanna Mikkola, M.D., Ph.D., shares her work in hematopoietic stem cells (HSCs) and their complex renewal process. Her research aims to unravel these cells' behavior in mice and humans, offering potential insights for future medical advancements. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39258]

Hanna Mikkola, M.D., Ph.D., shares her work in hematopoietic stem cells (HSCs) and their complex renewal process. Her research aims to unravel these cells' behavior in mice and humans, offering potential insights for future medical advancements. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39258]

Hanna Mikkola, M.D., Ph.D., shares her work in hematopoietic stem cells (HSCs) and their complex renewal process. Her research aims to unravel these cells' behavior in mice and humans, offering potential insights for future medical advancements. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39258]

Hanna Mikkola, M.D., Ph.D., shares her work in hematopoietic stem cells (HSCs) and their complex renewal process. Her research aims to unravel these cells' behavior in mice and humans, offering potential insights for future medical advancements. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39258]

Hanna Mikkola, M.D., Ph.D., shares her work in hematopoietic stem cells (HSCs) and their complex renewal process. Her research aims to unravel these cells' behavior in mice and humans, offering potential insights for future medical advancements. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39258]

BUFFALO, NY- January 10, 2024 – A new #editorial paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 24, entitled, “Exploring clonal hematopoiesis and its impact on aging, cancer, and patient care.” In this new editorial, researchers Julieta Elena Rodriguez, Jean Baptiste Micol and Capucine Baldini from Gustave Roussy discuss clonal hematopoiesis. Clonal hematopoiesis (CH) is a term that refers to the presence in blood cells of hematologic malignancy-associated somatic mutations without fulfilling the diagnostic criteria of hematologic disease. Emerging evidence suggests that CH is a consequence of an expansion of cells harboring initiating driver mutations, potentially linked to the aging hematopoietic system. While these detectable somatic mutations are rare in individuals under 40 years old, they become increasingly prevalent in the elderly population, a term called age-related clonal hematopoiesis (ARCH), reaching up to 18.4% in those aged 90 years or older. Aging itself is a significant stressor associated with CH, particularly in individuals over 70 years old. DNMT3A, TET2, and ASXL1 mutations are more common with advancing age. “Recent evidence also indicates that CH may play a role in solid tumors, such as an increased risk of incident lung cancer [4]. While initial studies associated CH mutations with worse survival outcomes [5], newer findings suggest that solid tumor patients with CH may experience longer survival [6]. However, the underlying mechanisms behind this relationship remain to be elucidated.” DOI - https://doi.org/10.18632/aging.205404 Corresponding author - Capucine Baldini - capucine.baldini@gustaveroussy.fr Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205404 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, clonal hematopoiesis, solid tumors About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com​​ and connect with us: SoundCloud - https://soundcloud.com/Aging-Us Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM

Anna Beaudin, Ph.D., delves into the intricacies of how prenatal inflammation impacts the immune system's blueprint, shaping its long-term function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39257]

Anna Beaudin, Ph.D., delves into the intricacies of how prenatal inflammation impacts the immune system's blueprint, shaping its long-term function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39257]

Anna Beaudin, Ph.D., delves into the intricacies of how prenatal inflammation impacts the immune system's blueprint, shaping its long-term function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39257]

Anna Beaudin, Ph.D., delves into the intricacies of how prenatal inflammation impacts the immune system's blueprint, shaping its long-term function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39257]

Anna Beaudin, Ph.D., delves into the intricacies of how prenatal inflammation impacts the immune system's blueprint, shaping its long-term function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39257]

Anna Beaudin, Ph.D., delves into the intricacies of how prenatal inflammation impacts the immune system's blueprint, shaping its long-term function. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39257]

Join us for our first episode of 2024 as we welcome Dr. Alex Bick, Assistant Professor of Medicine in the Division of Genetic Medicine at Vanderbilt University. In this episode, we will explore the impact of clonal hematopoiesis on cancer and cardiovascular health, examine the integration of genomics in healthcare and preventative medicine, and discuss a recent finding from the Million Veterans Program of a modifier variant in APOL1 kidney disease.

In this week's episode we'll uncover the clinical and pathological profile of a new disorder similar to VITT, or vaccine-induced thrombocytopenia and thrombosis. Then, we'll discuss real-world outcomes in patients with large B-cell lymphoma treated with tafasitamab and lenalidomide. Finally we'll learn about how advances in technology help unravel the spatial biology of bone marrow. 

Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]

Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]

Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]

Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]

Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]

Siddhartha Jaiswal, M.D., Ph.D., discusses clonal hematopoiesis and its impact on aging and diseases. Jaiswal highlights the role of genetic variations, focusing on a specific gene, TET2, and its link to clonal expansion. He explains that certain genetic variations can slow clonal expansion, potentially offering insights into treatments or interventions to mitigate its effects. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39260]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

Leonard Zon, M.D., discusses cutting-edge research on the intricate relationship between macrophages, stem cells, and the development of leukemia using the zebrafish model. He delves into the fascinating interactions between these cell types, highlighting the role of a "don't eat me" signal and the influence of the leukemic niche. Through cellular barcoding and single-cell RNA sequencing, he unveils a potential therapeutic target which may offer promising insights into treating leukemia by disrupting the stromal activities that support it. Zon showcases the power of zebrafish models in advancing our understanding of hematopoiesis and cancer, promising new avenues for research and treatment. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39064]

The 5th International Workshop on Acute Leukemias (iwAL 2023) took place in San Diego, CA, and brought together leading experts... The post iwAL 2023 Session I: Clonal hematopoiesis in AML, early detection and potential therapeutics appeared first on VJHemOnc.

Tune in to the Hematopoiesis podcast to hear a conversation about the increasingly relevant topic of geriatric hematology. Many blood disorders and hematologic malignancies are diseases of older adults, and in this introduction to geriatric hematology, Drs. Maya Abdallah and Ajay Major talk about “staging the aging.”Music: “Somebody New” RYYZN (www.toneden.io/ryyzn/post/somebody-new-copyright-free). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/.

In this week's episode, we'll learn more about poverty and relapse risk in children with ALL, discuss eligibility criteria and enrollment of diverse racial and ethnic populations in multiple myeloma clinical trials, and learn more about clonal hematopoiesis in VEXAS syndrome.

Join Physician Scientist and Nobel Laureate Dr. Bill Kaelin and Dr. Eric Vick of the ASH Trainee Council to discuss choosing your target as a physician scientist, discussing your choice of target in your career and in your scientific exploration.Music: “Somebody New” RYYZN (www.toneden.io/ryyzn/post/somebody-new-copyright-free). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/.

Commentary by Dr. Valentin Fuster

In this episode, Trainee Council Chairs, Drs. Becky Zon and Ajay Major, interview Dr. Nancy Berliner, Blood Editor-in Chief and Dr. Andrew Roberts, Blood Deputy Editor, on their careers in academic editing and publishing, including career development tips for trainees who are interested in a career in publishing.

In this week's episode we'll discuss the benefits of early diagnosis and hematopoietic stem cell transplant in patients with hypomorphic RAG deficiency, learn more about EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy, and analyze the associations between clonal hematopoiesis and recurrent vascular events and death in patients with ischemic stroke. 

In the second episode of this Hematopoiesis Bench to Bedside series, Dr. Manuel Espinoza-Gutarra has conversations with Dr. Aaron Mitchell, Dr. Yousuf Zafar (@yzafar), Dr. Aju Mathew, and Dr. Nandita Khera (@khera_nandita), experts in the field of financial toxicity in cancer patients, who offer different perspectives regarding the impact of the financial costs of modern anticancer treatment puts on patients, how should we adequately measure it and how to tackle it.Music: “Somebody New” RYYZN (www.toneden.io/ryyzn/post/somebody-new-copyright-free). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/.

In this episode — which might or might not be the end of the world as we know it — Nurse Claire joins us to discuss newly acknowledged medical issues in the bodies of people who have accepted The Jab into their lives. Whether it's the theft of your immune system and health or the theft of your investments in sordid companies like FTX, the end is approaching with a velocity greater than that of high frequency trades in a NASDAQ computer. Get into the Church if you aren't yet, stay confessed, and prepare prudently in a spirit of peace and joy because great things await us! Links, Reading, and Video: Trans volleyball player almost kills an actual girl Edith Wilson: The De Facto President Skewed Fate and Hematopoiesis of CD34+ HSPCs in Umbilical Cord Blood Amid the COVID-19 Pandemic The Mark of The Beast Explained: MV = PQ, With Totalitarian Control of V(elocity)   Feedback: please send your questions, comments, suggestions, and happy news item to podcast@barnhardt.biz — or you can leave voicemail feedback at (302) 648-6373‬. (Alternate email addresses are supernerdmedia@protonmail.com and annbarnhardt@protonmail.com if you are looking for something more secure.) Supernerd Media produces the Barnhardt Podcast, hosts Ann's website, and more; if you got some value from these efforts and would like to return some value please visit SupernerdMedia.com to find out how to send a donation via a few other methods.

Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies.

Commentary by Dr. Valentin Fuster

In this episode of Hematopoiesis, Dr. Alexis Caulier has exciting conversations with three experts in the field about how early bench work on the genetic regulation of fetal hemoglobin led to the development of bedside gene therapies. Dr. David Nathan revisits the beneficial role of fetal hemoglobin to improve the clinical manifestations of hemoglobinopathies. Dr. Vijay Sankaran (@bloodgenes) highlights the great impact of studying gene regulatory networks in developing innovative gene therapies, and Dr. Courtney Fitzhugh (@CourtneyFitzhu1) emphasizes the importance and the specificities of clinical trials for innovative therapies.Music: “Somebody New” RYYZN (www.toneden.io/ryyzn/post/somebody-new-copyright-free). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/.

In this episode, we bring two experts in clonal hematopoiesis, Dr. Sid Jaiswal from Stanford University and Dr. Alex Bick from Vanderbilt University to dissect the biology, potential clinical implications, and future of clonal hematopoiesis.